Effect of Adalimumab Therapy on Psoriasis Patient

Sponsor
Sohag University
Study ID
NCT05889338
Status
Unknown

Conditions

  • Psoriasi

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • adalimumab and methotrexate — DRUG
    Adult patients (\> 18 years) with severe psoriasis who will start treatment with either adalimumab or methotrexate

Study Details

to evaluate the impact of adalimumab therapy on quality of life in patient with severe psoriasis.

Key Dates

Start date
Jun 30, 2023
Status verified
Jun 2023
Primary completion
Jan 31, 2024
Completion
Jan 31, 2024

Study Design

Enrollment
140 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Case: adults with severe psoriasis treated by adalimumab therapy.
  • Active Comparator: Control: adults with severe psoriasis treated by methotrexate therapy.

Primary Outcome Measure

Psoriasis Area and Severity Index [ Time Frame: 6 month ]

Central Contacts

  • Shimaa f Abdelhaleem, M.B.B.Ch
    01140017278
    [email protected]
  • Ramadan S Abdo Saleh, Professor